High-Resolution Genetics Identifies the Lipid Transfer Protein Sec14p as Target for Antifungal Ergolines.
Détails
Télécharger: journal.pgen.1006374.pdf (2361.10 [Ko])
Etat: Public
Version: Final published version
Etat: Public
Version: Final published version
ID Serval
serval:BIB_35AC0D8A3D2D
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
High-Resolution Genetics Identifies the Lipid Transfer Protein Sec14p as Target for Antifungal Ergolines.
Périodique
PLoS genetics
ISSN
1553-7404 (Electronic)
ISSN-L
1553-7390
Statut éditorial
Publié
Date de publication
11/2016
Peer-reviewed
Oui
Volume
12
Numéro
11
Pages
e1006374
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
Invasive infections by fungal pathogens cause more deaths than malaria worldwide. We found the ergoline compound NGx04 in an antifungal screen, with selectivity over mammalian cells. High-resolution chemogenomics identified the lipid transfer protein Sec14p as the target of NGx04 and compound-resistant mutations in Sec14p define compound-target interactions in the substrate binding pocket of the protein. Beyond its essential lipid transfer function in a variety of pathogenic fungi, Sec14p is also involved in secretion of virulence determinants essential for the pathogenicity of fungi such as Cryptococcus neoformans, making Sec14p an attractive antifungal target. Consistent with this dual function, we demonstrate that NGx04 inhibits the growth of two clinical isolates of C. neoformans and that NGx04-related compounds have equal and even higher potency against C. neoformans. Furthermore NGx04 analogues showed fungicidal activity against a fluconazole resistant C. neoformans strain. In summary, we present genetic evidence that NGx04 inhibits fungal Sec14p and initial data supporting NGx04 as a novel antifungal starting point.
Mots-clé
Antifungal Agents/pharmacology, Carrier Proteins/chemistry, Carrier Proteins/genetics, Cryptococcosis/drug therapy, Cryptococcosis/microbiology, Cryptococcus neoformans/drug effects, Cryptococcus neoformans/genetics, Cryptococcus neoformans/pathogenicity, Ergolines/chemistry, Ergolines/pharmacology, Humans, Lipid Metabolism/drug effects, Microbial Sensitivity Tests, Protein Conformation, Saccharomyces cerevisiae/chemistry, Saccharomyces cerevisiae/genetics
Pubmed
Open Access
Oui
Création de la notice
06/12/2016 17:37
Dernière modification de la notice
20/08/2019 13:23